MAPT and Alzheimer disease: Under this A/T/N framework, AD diagnosis is assessed by the presentation of amyloid pathology (A+, by amyloid PET or in CSF), by the presence or absence of tau fibrillation (T, by PET or phospho-tau in CSF), and the extent of neurodegeneration (N, by structural MRI or total tau in CSF).